Residual Exacerbations With Mepolizumab

Recruiting now

Conditions studied: Asthma

In brief

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Key facts

Study ID

NCT04578171

Run by

Laval University

People needed

60

Starts

2021-07-06

Expected to finish

2028-01-01

Last updated by the study team

2025-02-10

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
• Eligible for mepolizumab treatment
• Able and willing to sign the informed consent form

You may not qualify if…

• Any respiratory disease apart from asthma
• Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome

Where it is running

• Institut universitaire de cardiologie et de pneumologie de Québec — Québec, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.